Last update 01 Nov 2025

MG-O-1001

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
MG O 1001, MG-O-1001, TO-O-1001
Target
ROCK1
Action
inhibitors
Mechanism
ROCK1 inhibitors(Rho-associated protein kinase 1 inhibitors)
Therapeutic Areas
Eye Diseases
Active Indication
Glaucoma
Inactive Indication
Glaucoma, Open-Angle
Originator Organization
Metagone Biotech, Inc.
Active Organization
Theratocular Biotek Co., Ltd.Metagone Biotech, Inc.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with MG-O-1001
NCT05456724
/ Unknown statusPhase 1/2
A 3-Part, First-in-human, Double-Blind, Randomized, and Placebo-Controlled Study Assessing the Safety, Tolerability, and Efficacy of TO-O-1001 Ophthalmic Solution in Healthy Subjects and in Patients With Open-Angle Glaucoma or Ocular Hypertension
100 Clinical Results associated with MG-O-1001
Login to view more data
100 Translational Medicine associated with MG-O-1001
Login to view more data
100 Patents (Medical) associated with MG-O-1001
Login to view more data
100 Deals associated with MG-O-1001
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Glaucoma, Open-AnglePhase 2
Australia
Theratocular Biotek Co., Ltd.
04 Aug 2022
GlaucomaPhase 2-
Theratocular Biotek Co., Ltd.
-
GlaucomaPhase 2-
Metagone Biotech, Inc.
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT05456724 (ARVO2024)
Phase 1/2
Glaucoma, Open-Angle
9
tflfzhjmst(kekoaxkplb) = In healthy volunteers, After 7 days of 0.1% TO-O-1001 dosing, the mean IOP has reduced 29.2% to 10.5±1.3 mmHg. In the P2 ongoing trial, After 14-day treatment, the average IOP reduction is 6.5±3 mmHg (Day 1) and 7.8±4 mmHg (Day 14), and the IOP-lowering effect up to 12 mmHg (Day 14). fxqhiqmbjm (nzaegdjfjn )
Positive
06 May 2024
安慰剂
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free